Liver organoid model to test drug-induced liver fibrosis and other liver diseases

Chronic liver diseases, such as alcoholic liver disease, non-alcoholic fatty liver disease and viral hepatitis, lead to liver fibrosis and subsequent liver cirrhosis. According to WHO, liver cirrhosis accounts for 1.8% of all deaths in Europe, causing around 170.000 deaths/year, with a higher prevalence in east and west Europe. However, in terms of fibrosis, no pharmacological agent has been approved for routine use in a clinical context. In addition, no good in vitro models of fibrosis exist that can predict a fibrotic potential of a compound.

Current models for in vitro fibrosis consist of simple mono-layer cultures of rodent hepatic stellate cells (HSC) the key players in fibrosis, but ignoring the role of other events and cells such as hepatocyte injury. Rodent models give an integrative testing environment but introduce species discrepancies in terms of human outcome. Hence, there is a particular need for assays suitable for identifying human pro-fibrotic and anti-fibrotic compounds, taking into account not only the direct but also the indirect activation of HSCs.

Solution: novel human hepatic organoid culture

The Liver Cell Biology team (LIVR) of the VUB developed a novel human hepatic organoid culture to detect drug-induced liver fibrosis. These organoids cultured in 96-well plates consist of human hepatocytes and primary HSCs which have been characterized for their competence and functionality for up to 21 days.

These organoids can pinpoint drug-induced hepatic injury but also drug-induced liver fibrosis upon single and repeated exposures of compounds. The size of the test unit (1 well in 96-well plate) allows for screening of multiple compounds and different conditions. Currently, the organoids are being tested for the detection of other liver diseases such as steatosis, phospholipidosis, cholestasis and viral hepatitis.

Competitive advantages

  • First in vitro culture model to detect drug-induced human liver fibrosis
  • Compatible with mid-highthroughput screening systems
  • Suitable for single and repeated (long-term) compound exposures
  • Well characterized system (download key paper here)

What we are looking for?

  • Setting up joint R&D projects with industrial partners to screen for anti/pro-fibrotic compounds.
  • Out-licensing of the 3D co-culture model, or establishing this technology on site of industrial partners on a fee-for-service or collaborative basis

Interested parties can contact

VUB TechTransfer
Hugo Loosvelt
[T]: +32 (0)2 629 38 65 or 22 07
[E]: hugo.loosvelt@vub.ac.be

Liver Cell Biology team – LIVR
Leo van Grunsven
[E]: lvgrusnv@vub.ac.be
Sofia Batista Leite
[E]: sobatist@vub.ac.be

Patent details

PCT/EP2015/062551 “HUMAN HEPATIC 3D CO-CULTURE MODEL AND USES THEREOF”; The claimed invention describes “a 3D co-culture of hepatic cells and stellate cells in which the stellate cells are in excess of the hepatocytes” and that “the cultures are used for the screening of pro- or anti-fibrotic compounds”.

Download a printable pdf here.